Review



anti hbs antibody elisa kit  (Bio-Rad)


Bioz Verified Symbol Bio-Rad is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 94
      Buy from Supplier

    Structured Review

    Bio-Rad anti hbs antibody elisa kit
    Progressive reduction in serum HBsAg detected with <t>ELISA</t> was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Anti Hbs Antibody Elisa Kit, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 79 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti hbs antibody elisa kit/product/Bio-Rad
    Average 94 stars, based on 79 article reviews
    anti hbs antibody elisa kit - by Bioz Stars, 2026-02
    94/100 stars

    Images

    1) Product Images from "HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination"

    Article Title: HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

    Journal: Molecular Therapy. Methods & Clinical Development

    doi: 10.1016/j.omtm.2025.101646

    Progressive reduction in serum HBsAg detected with ELISA was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Figure Legend Snippet: Progressive reduction in serum HBsAg detected with ELISA was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.

    Techniques Used: Enzyme-linked Immunosorbent Assay, Western Blot, Control, Positive Control, Injection, Negative Control, Blocking Assay



    Similar Products

    anti hbs antibody elisa kit  (Bio-Rad)
    94
    Bio-Rad anti hbs antibody elisa kit
    Progressive reduction in serum HBsAg detected with <t>ELISA</t> was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Anti Hbs Antibody Elisa Kit, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti hbs antibody elisa kit/product/Bio-Rad
    Average 94 stars, based on 1 article reviews
    anti hbs antibody elisa kit - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    anti hbs antibody elisa kit 578  (Bio-Rad)
    94
    Bio-Rad anti hbs antibody elisa kit 578
    Progressive reduction in serum HBsAg detected with <t>ELISA</t> was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Anti Hbs Antibody Elisa Kit 578, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti hbs antibody elisa kit 578/product/Bio-Rad
    Average 94 stars, based on 1 article reviews
    anti hbs antibody elisa kit 578 - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    elisa kits for hbsag, anti-hbs, and anti-hbc  (Abbott Laboratories)
    90
    Abbott Laboratories elisa kits for hbsag, anti-hbs, and anti-hbc
    Progressive reduction in serum HBsAg detected with <t>ELISA</t> was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Elisa Kits For Hbsag, Anti Hbs, And Anti Hbc, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elisa kits for hbsag, anti-hbs, and anti-hbc/product/Abbott Laboratories
    Average 90 stars, based on 1 article reviews
    elisa kits for hbsag, anti-hbs, and anti-hbc - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    monolisatm anti hbs plus elisa kit  (Bio-Rad)
    94
    Bio-Rad monolisatm anti hbs plus elisa kit
    Progressive reduction in serum HBsAg detected with <t>ELISA</t> was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Monolisatm Anti Hbs Plus Elisa Kit, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monolisatm anti hbs plus elisa kit/product/Bio-Rad
    Average 94 stars, based on 1 article reviews
    monolisatm anti hbs plus elisa kit - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier
    anti-hbs elisa kit  (Autobio Diagnostics)
    90
    Autobio Diagnostics anti-hbs elisa kit
    Progressive reduction in serum HBsAg detected with <t>ELISA</t> was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Anti Hbs Elisa Kit, supplied by Autobio Diagnostics, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-hbs elisa kit/product/Autobio Diagnostics
    Average 90 stars, based on 1 article reviews
    anti-hbs elisa kit - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    elisa test anti-hbs elisa kit  (Pishtaz Teb)
    90
    Pishtaz Teb elisa test anti-hbs elisa kit
    Progressive reduction in serum HBsAg detected with <t>ELISA</t> was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Elisa Test Anti Hbs Elisa Kit, supplied by Pishtaz Teb, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/elisa test anti-hbs elisa kit/product/Pishtaz Teb
    Average 90 stars, based on 1 article reviews
    elisa test anti-hbs elisa kit - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    anti-hbs elisa kit reagent  (Abbott Laboratories)
    90
    Abbott Laboratories anti-hbs elisa kit reagent
    Progressive reduction in serum HBsAg detected with <t>ELISA</t> was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Anti Hbs Elisa Kit Reagent, supplied by Abbott Laboratories, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/anti-hbs elisa kit reagent/product/Abbott Laboratories
    Average 90 stars, based on 1 article reviews
    anti-hbs elisa kit reagent - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier
    monolisa hbsag elisa kit  (Bio-Rad)
    94
    Bio-Rad monolisa hbsag elisa kit
    Progressive reduction in serum HBsAg detected with <t>ELISA</t> was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.
    Monolisa Hbsag Elisa Kit, supplied by Bio-Rad, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/monolisa hbsag elisa kit/product/Bio-Rad
    Average 94 stars, based on 1 article reviews
    monolisa hbsag elisa kit - by Bioz Stars, 2026-02
    94/100 stars
    		  Buy from Supplier

    Image Search Results


    Progressive reduction in serum HBsAg detected with ELISA was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.

    Journal: Molecular Therapy. Methods & Clinical Development

    Article Title: HBVZ10, an AAV8 vector-based new HBV therapy candidate for cccDNA elimination

    doi: 10.1016/j.omtm.2025.101646

    Figure Lengend Snippet: Progressive reduction in serum HBsAg detected with ELISA was corroborated with western blot results and supported by intracellular HBsAg reduction (A) Progressive reduction of serum HBsAg detected by ELISA in mouse 838 (A1 orange) who received a single dose of HBVZ10 combined with 12-week ETV and was corroborated by western blot (A2). Mouse 831 was a mock-treated control. 100 × Hep: Positive control with concentrated viral particles from the HepAD38 cell medium. (B) Progressive reduction of serum HBsAg detected by ELISA in mouse 970 (B1 orange) who received mouse anti-HBs antibody monotherapy at a dose of 250 μg/injection triweekly for 9 consecutive times and was corroborated by western blot (B2). Mouse 907 was a mock-treated control. ADR and ADW: HBV positive human sera. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 35526 and 34477, negative human sera. X, no sample lane. Intrahepatic HBsAg was undetectable by ELISA (C1) in lysates (30 μL each) from seven mice that achieved an HBsAg − /anti-HBs + serum status. Consistently, western blot analysis (C2) of 40 μL liver lysates showed either undetectable or markedly reduced HBsAg levels in these seven mice compared with three untreated controls (mice 907, 987, and 471). (D) Intrahepatic HBc protein analyzed using western blot. 100xHepAD, Positive control with concentrated viral particles from HepAD38 cell medium. 100× GFP-HepG2 cell lysate, negative control. BHK-020, Uninfected liver lysate as negative control. X, no sample lane. Mice 812, 813, 814, 824, and 838 in green were the five mice with progressive reduction of serum HBsAg level upon blocking cccDNA replenishment. Mice 831 and 805 in blue were mock treated. Mouse 833 in purple received a single dose of HBVZ10 monotherapy on day 44pi. Four liver lysates from each liver were analyzed, and numbered as 1, 2, 3, and 4 or 5, 6, 7, and 8 or 11, 12, 13, and 14, respectively after mouse ID number.

    Article Snippet: Serum anti-HBs antibody levels were quantified using the anti-HBs antibody ELISA kit (MONOLISA Anti-HBs EIA, cat. no. 25220, Bio-Rad) with corresponding calibrators (cat. no. 25219, Bio-Rad), following the manufacturer’s instructions.

    Techniques: Enzyme-linked Immunosorbent Assay, Western Blot, Control, Positive Control, Injection, Negative Control, Blocking Assay